Free Trial
NASDAQ:PROK

ProKidney Q4 2023 Earnings Report

ProKidney logo
$0.64 -0.05 (-6.67%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ProKidney EPS Results

Actual EPS
-$0.09
Consensus EPS
-$0.19
Beat/Miss
Beat by +$0.10
One Year Ago EPS
N/A

ProKidney Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ProKidney Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Thursday, March 21, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

ProKidney's Q1 2025 earnings is scheduled for Friday, May 9, 2025

ProKidney Earnings Headlines

ProKidney Corp.
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.
ProKidney reports FY24 EPS (62c), consensus (59c)
See More ProKidney Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ProKidney? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ProKidney and other key companies, straight to your email.

About ProKidney

ProKidney (NASDAQ:PROK), a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

View ProKidney Profile

More Earnings Resources from MarketBeat